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ABSTRACT 
 Cannabidiol, also known as CBD, first gathered national spotlight after Charlotte 
Figi and her mother Paige were able to find two physicians willing to prescribe CBD to 
treat Charlotte’s seizures.  Charlotte suffered from Dravet Syndrome, but was able to find 
relief from CBD, which decreased the number and severity of her seizures.  This sparked 
national interest and was the catalyst that lead to research and changes surrounding CBD 
uses and legality.  Cannabidiol is a single cannabinoid that is found within the Cannabis 
sativa plant family—the same family that includes marijuana.  This cannabinoid differs 
from tetrahydrocannabinol (THC) and does not provide a high to its users, which depends 
on the receptors activated by each cannabinoid. 
 To date, Epidiolex® is the only FDA approved drug which contains non-synthetic 
cannabidiol extract.  The drug has a very narrow indication and is approved only for rare 
forms of pediatric seizures such as Lennox-Gastaut Syndrome and Dravet Syndrome.  
Non-FDA-approved uses of CBD vary based on anecdotal evidence.  Some commonly 
reported uses for CBD include easing anxiety, helping with sleep, and clearing up acne or 
skin blemishes.  Thousands of CBD products that do not have FDA approval are on the 
market and are available to consumers. This largely came about due to the passage of the 
2018 Farm Bill, which made hemp federally legal in the United States—essentially 
federally legalizing CBD.  However, not all states have legalized all forms of CBD. 
 For example, Mississippi enacted Harper Grace’s Law in 2014 which approves 
cannabidiol in limited quantities and indications if prescribed by a licensed physician.  It 
also led to clinical trials for CBD in epilepsy to be conducted at the University of 
 v 
Mississippi Medical Center in Jackson, Mississippi, presumably for a competitor product 
of Epidiolex®.  However, no other CBD products are legal for use in Mississippi, despite 
the prevalence of CBD stores and CBD products in state-permitted pharmacies.  Things 
may change, however, as Mississippi is set to have medical marijuana on its ballot in 
November of 2020.  If passed, this would not only allow medical marijuana to be 
prescribed for certain medical indications, but presumably CBD as well. 
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INTRODUCTION 
Charlotte’s Web 
Charlotte Figi was one of two children born to Paige Figi on October 18, 
2006.  Charlotte and her twin brother were born healthy and happy.  Then three months 
later Charlotte began having seizures.  Her first seizure was 30 minutes long, but soon her 
seizures would last hours and frequently land her in the hospital.  No doctor could give 
her a diagnosis.  No tests were coming back with positive results.  Yet, Charlotte was still 
having constant seizures, and the seizures were becoming increasingly severe in length 
and strength.  Finally, one doctor suggested that Charlotte might have Dravet Syndrome.  
Dravet syndrome is an exceptionally rare case of intractable epilepsy.  This was the first 
attempt at a diagnosis for Charlotte and soon she was seeing a neurologist at the 
Children’s Hospital in Colorado who conducted a scan for the SCN1A gene mutation 
which is common in Dravet syndrome cases.  For the first time, a test came back positive.  
As devastating a diagnosis as it was, Charlotte’s mother, Paige, was relieved to finally 
have an answer.  Now she could finally go about finding the next step to help her 
daughter.  A Dravet Syndrome specialist in Chicago suggested Charlotte begin a 
ketogenic diet, which is high in fat and low in carbs.  This would cause her body to 
produce more ketones which naturally suppress seizures (Young).   
At first there was a noticeable drop in the number of seizures Charlotte 
had.  However, there was also a noticeable decrease in her bone density and she 
experienced reduced immunity.  Two years into the diet, her seizures came back.  Paige 
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began researching anything and everything having to do with Charlotte’s condition.  She 
happened upon an article about a boy from California treating his Dravet syndrome with 
cannabis.  At first Paige was hesitant, but when weighing her options, she decided it was 
worth trying.  The cannabis used for treatment was high in CBD and low in THC, both 
different cannabinoids of marijuana.  Colorado approved the legalization of marijuana for 
eight medical purposes in 2000, one of those purposes being seizures.  Paige decided to 
apply for the program and plead Charlotte’s case.  It was no easy pitch.  Because she was 
so young (5 years old at the time) no doctor was willing to sign off on it because of her 
age and the unknown long-term results.  After searching, she found two doctors willing to 
approve her program application for the same reason as Paige was willing to apply—
nothing else had worked.  Once approved, the results were stunning.  Charlotte’s seizures 
slowed to two or three times a month, mostly in her sleep.  She regained her immune 
system and bone density and began developing normally.  She continues to take two 
doses a day with her meals.  The strain of cannabis used to treat her, R4, was named 
Charlotte’s Web, representing the tangled path she went through to find a cure for her 
seizures (Young). 
What is CBD? 
Cannabidiol, or CBD as it is commonly known, is a specific cannabinoid found in 
plants from the Cannabis sativa family, such as hemp and marijuana.  Cannabinoids, 
sometimes also referred to as phytocannabinoids, are naturally occurring chemical 
substances which possess biological activity (Merriam-Webster).  Cannabinoids such as 
CBD are chemicals produced by the flowers of the cannabis plant that emulate some of 
the natural neurotransmitters of the body, endocannabinoids (Rahn).  Endocannabinoids, 
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which are present in all vertebrates, are responsible in part for maintaining the 
homeostasis of our bodies (UCLA Health).  The endocannabinoid system (ECS) helps 
mediate the internal cell to cell communication and aids in the stabilization of a variety of 
body processes such as metabolism, memory, appetite, stress, pain and sleep (Rahn, 
UCLA Health).  Endocannabinoids bind to receptors located throughout our bodies.  The 
receptors are generally divided into Cannabinoid-1 Receptors (CB1) and Cannabinoid-2 
Receptors (CB2).  The central nervous system, consisting of the brain and nerves, houses 
the CB1 receptors while the remainder of the body houses the CB2 receptors.  
Understanding how our endocannabinoid system works, including how our receptors 
work, has allowed for distinctions to be made among the many various cannabinoids.   
The two most common cannabinoids are CBD and THC, known as cannabidiol 
and tetrahydrocannabinol respectively.  THC is the main psychoactive cannabinoid in 
marijuana and other Cannabis sativa plants which provides a “high” to its users 
(Holland).  This high is present because of THC’s ability to tightly bind CB1 receptors in 
the central nervous system, specifically the brain.  THC and CBD have very similar 
structures and are in fact made up of the exact same composition of elements, only 
arranged slightly differently (Holland).  Both structures are similar to natural 
endocannabinoids made by the body and allow for interaction with CB1 and CB2 
receptors.  Due to the differences in structures, THC has more of an affinity for the CB1 
receptors and CBD has more of an affinity for the CB2 receptors.  It is unknown for 
certain if CBD will bind directly to the CB1 receptors in the central nervous system, but 
it is known that CBD will interact indirectly, lessening the effects of THC and reducing 
epileptic seizures (Project CBD).  CBD is currently being examined for its medicinal 
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properties and as an alternative to other medications for conditions such as chronic pain, 
seizures, sleep-disorders, and many more.  Currently, Epidiolex® is the only FDA 
approved drug on the market containing actual cannabidiol (CBD) from the Cannabis 
plant.  This approval came on June 25 of 2018, and Epidiolex® is specifically indicated 
for treatment of two rare and severe forms of pediatric epilepsy, Lennox-Gastaut 
Syndrome and Dravet Syndrome, in patients at least 2 years of age (Commissioner, 
Project CBD).  There are other drugs on the market such as Marinol, Nabilone, and 
Rimonabant which are synthetic cannabinoid drugs that mimic other cannabinoids and 
endocannabinoids, but the active components in these medicines are not derived directly 
from the Cannabis plant like the phytocannabinoids in Epidiolex® (Rahn). 
Non-FDA approved products containing CBD are available as supplements and 
vitamins, marketed towards curing various ailments, soothing aches and pains, and even 
clearing skin.  Among these products consumers will commonly encounter terminology 
such as “CBD rich” and “CBD dominant.”  While similar sounding, these terms are used 
to distinguish differing amounts of THC in products by comparing ratios of 
CBD:THC.  A product labelled “CBD-rich” has high CBD and THC contents, but there is 
usually more CBD than THC (about 4% more dry weight) (Rahn).  A product labelled 
“CBD-dominant” on the other hand refers to products with an overwhelming amount of 
CBD and minimal THC content. 
Terms and Classifications 
Many terms surrounding CBD are used interchangeably, but are actually distinct 
and separate terms and need to be defined.  The most common terms are hemp, cannabis, 
marijuana, and weed.  Cannabaceae, the hemp family, includes the Cannabis genus under 
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which distinct species such as Cannabis L. (hemp) and Cannabis sativa L. (marijuana) 
fall (Classification).  Cannabis the genus can be thought of as a general, encompassing 
term that contains multiple subsets including marijuana and hemp (CBD Web).  Between 
these two, the most easily quantifiable distinction comes with how much THC is present 
in the plant.  Anything greater than 0.3% THC dry weight qualifies as marijuana.  
Anything less than 0.3% THC dry weight qualifies as hemp.  Because THC is mainly 
produced in the flowering parts of the Cannabis plants, US law denotes hemp as the 
stalks, stems, and sterilized seeds of cannabis sativa and marijuana as the leaves, flowers 
and viable seeds of Cannabis sativa (Stanford).  Weed is one of many slang words 
referring to marijuana which has origins in 1930s Harlem, but does not refer to a specific 
species at all (Wright). 
Scheduling of substances directly relates to their potential for abuse and 
dependence and is listed on a scale from I-V with I having the highest potential for abuse 
and physiological and psychological dependence and 5 having the least (DEA).  Cannabis 
has previously been listed as a Schedule I drug since 1970, which implies that there is 
currently no medical value or accepted reason for using the substance (DEA). 
Hypothesis 
 The purpose of this narrative review is to determine if the following hypothesis 
can be supported: That CBD has potential to clinically treat numerous conditions, but 
that such potential needs to be explored in a rigorous and legal way.  
Data Collection 
 Data for this review comes from easily accessible information which is available 
to the public.  Most of my data can be found online, through various websites that are 
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sited throughout this paper and can be found in the references section.  Other data came 
from magazine readings, advertisements, and personal observations and interactions.  My 
interactions included informally interviewing store owners who stocked and sold CBD 
products, as well as speaking with people who are currently using CBD for their personal 
health in some way.  These personal anecdotes were compared to anecdotal evidence 
from additional online sources. 
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THERAPEUTIC USES OF CANNABIDIOL 
Clinical Uses of CBD 
Cannabidiol is marketed to heal and improve many ailments, but what does CBD 
really treat?  There are many personal anecdotes documenting the potential uses of CBD, 
but clinical studies and clinical data on cannabidiol are fairly limited.  The most 
substantial clinical data comes from clinical trials related to the treatment of epilepsy 
which lead to the FDA approval of Epidiolex® in June of 2018 (Centers for Drug 
Evaluation and Research).  An interesting clinical study investigated the effects of the 
human endocannabinoid system as a cancer target.  The results could have implications in 
the use of CBD as a cancer therapy, since CBD interacts with the body’s natural 
endocannabinoid system receptors CB1 and CB2 (Laezza, et al.)  However, this 
preliminary data needs to be researched more before drawing firm conclusions.  Sativex 
is a new investigational drug currently in clinical trials which aims to reduce pain in 
cancer patients with a poor response to opioid medications.  Sativex has THC as well as 
CBD components (GW Pharmaceuticals). 
There have also been a few pre-clinical studies to explore the effectiveness of 
CBD in neurological diseases such as Alzheimer's Disease, Parkinson’s Disease, and 
Multiple Sclerosis (Mannucci, et al.).  The findings suggested that because of the anti-
inflammatory qualities of CBD and the antioxidant properties, CBD could be a 
breakthrough in neuroprotective agents, but there would need to be clinical studies 
conducted and more data found before this could be confirmed (Mannucci, et al.).  Below 
is a 2019 chart from Hemp Industry Daily, which shows highlights the pharmaceutical 
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interest in clinical research of cannabidiol as well as which companies have completed, 
active, or future study trials lined up.  GW Pharmaceuticals currently has the highest 
number of completed trials and is the company that completed clinical trials for 
Epidiolex®.  GW pharmaceuticals is also the company currently conducting trials for 
Sativex. 
Figure 1: US Pharmaceutical Companies 
 
From: https://hempindustrydaily.com/hemp-cbd-companies-lining-up-university-
research-to-validate-anecdotal-evidence/  
The current clinical data on the uses of CBD is fairly limited, which has led to 
increased attention on personal anecdotes of success/treatment with CBD and products 
containing CBD.  A lot of information circulating through the general population 
concerning the medicinal properties of CBD come from personal testimonies of how the 
compound has worked to fix their problems.  There are common trends and abundant 
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stories of CBD helping with the same conditions, such as anxiety, sleep disorders, and 
chronic pain, to list a few.  Despite the wide array of potential treatments, CBD 
surprisingly is not reported to have many side effects.  These anecdotal stories provide a 
starting point to begin researching the effects of CBD in a clinical setting to determine 
the true range of this drug.  A few examples from Centennial Spotlight include stories on 
how CBD helps with: 
• Improved sleep 
• Reducing aches and pains, arthritis, post-workouts 
• Anti-inflammatory skin care creams, anti-aging creams 
• Relaxing, reducing anxiety and stress, PTSD alleviation  
While none of these are confirmed indications for the use of cannabidiol (currently 
seizures are the only medically acceptable indication with clinical data), it is interesting 
to notice how the general population is seeing effects of cannabidiol in their everyday 
lives (Centennial Spotlight).  Although none of these anecdotal stories are backed by 
clinical data as of now, they may pave the way for new areas of research related to the 
uses and benefits of CBD. 
Epidiolex®  
Epidiolex®, the only FDA approved drug containing non-synthetic CBD derived 
directly from Cannabis plants, is indicated for two severe and rare forms of pediatric 
epilepsy, Dravet syndrome and Lennox-Gastaut syndrome (Center for Drug Evaluation 
and Research).  This schedule V drug is approved in patients over 2 years of age and is 
available as a liquid solution which is to be taken twice daily for seizure control 
(Slowiczek).  Doses are based on a patient’s weight, severity of seizures, and tolerability 
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of the drug.  Doses can be increased if needed, but it is recommended to start at a low 
dose to gauge patient response.  The clinical studies results showed a statistically 
significant (p value of 0.001) decrease in seizures for patients taking Epidiolex® than for 
patients on a placebo.  This clinical study did not take into account race because 86 
percent of participants were white, but was shown to work similarly in males and females 
and to work similarly in those above and below the age of 18.  There were four clinical 
trials that led to the approval of Epidiolex® by the FDA.  Double-blind clinical trials 
(neither health care provider or patient knew what drug was being received) were done in 
Europe and the US and consisted of 550 patients over 58 sites.  The patients were about 
50/50 male to female (real values are 46/54 M/F).   
How were the trials designed? Epidiolex® was evaluated throughout four clinical 
trials; the first three evaluated safety and efficacy, the fourth was purely testing for the 
safety of the drug.  The subjects/patients in the first two trials suffered from Lennox-
Gastaut syndrome and were having uncontrolled seizures due to lack of effectiveness on 
their current treatments.  These subjects were assigned randomly into a treatment and 
placebo group in a double-blind study.  Both groups took two doses per day, and doses 
for both groups were increased every other day for two weeks to reach the desired 
dose.  After reaching the desired dose, subjects remained there for 12 weeks.  The 
difference in the number of seizures between the placebo and treatment group and their 
respective baselines were measured and used to determine the efficacy of Epidiolex®. 
Trials three and four were conducted for patients who suffered from uncontrolled 
seizures on their current medication for Dravet syndrome.  Trial 3 was conducted the 
exact same as trials 1 and 2, but for patients with Dravet syndrome.  Trial 4 was a study 
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to determine the safety and side effects of certain doses of Epidiolex®.  In this double-
blind study, subjects were randomly assigned to take one of three possible doses of 
Epidiolex® twice daily for 3 weeks. 
 Mild and severe side effects may occur when taking Epidiolex®.  Because 
Epidiolex® was approved through clinical studies, these side effects are known.  Mild 
side effects include feeling drowsy or lacking energy, generally feeling under-the-
weather, loss of appetite, and diarrhea.  Mild side effects are expected to lessen over the 
course of a few days to a couple of weeks.  While severe side effects of Epidiolex® are 
rare, reported side effects included sedation, liver problems, severe allergic reactions, and 
suicidal thoughts (Slowiczek).  The risk of most side effects is increased with higher 
doses of Epidiolex®. 
CBD and Animals 
There are no currently approved cannabidiol containing drugs for animals.  While 
many people use CBD for anxiety and other common conditions of animals, it is 
currently illegal under the Food, Drug, and Cosmetic Act (FDCA).  The FDCA states that 
any product containing CBD, THC, or other components of marijuana are currently not 
allowed in food of any sort for human or animal consumption (FDA).  As far as 
veterinary recommendations, the topic must be brought up by the patient before the vet 
may endorse trying CBD products for pets (Consumer Reports).  If looking to try 
cannabidiol for a pet, recommendations are to seek out products marketed for animals 
that avoid other ingredients which may be toxic to animals.  Other recommendations 
include dosing gradually and watching to see how each pet responds individually to 
treatment with CBD.  Currently there is even less known about the safety and 
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effectiveness of CBD in animals than there is in humans.  This is an emerging market 
which is expanding as pet owners’ anecdotal stories of pets with lessened anxiety, 
improved movement due to decreased pain of arthritis, and decreased seizure activity 
grow (Consumer Reports). 
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FEDERAL REGULATION OF CANNABIDIOL 
Overview 
While CBD is found virtually everywhere now, ranging from gas stations to 
dispensaries to CBD specific stores, the legality surrounding CBD is not clear.  There is a 
lot of uncertainty on which laws apply in which states and where the ever-changing fine 
line between legal and illegal stands.  
Agricultural Improvement Act of 2018 (2018 Farm Bill) 
Every five years, Congress passes a bill stating and amending policies governing 
national agriculture, nutrition, conservation, and forestry.  The Agricultural Improvement 
Act of 2018 is the current version, which will last through 2023.  It is often cited and 
commonly known as the “2018 Farm Bill.”  This bill is of interest because of the extent 
to which hemp is included and discussed.  The term “hemp” appears 48 times throughout 
the 2018 Farm Bill. 
The term hemp is clearly defined in section 11101 of Title 11 and references 
section 297A of the Agricultural Marketability Act of 1946 which states that hemp is 
defined as any part of the plant Cannabis sativa L. with less than 0.3% delta-9 
tetrahydrocannabinol (THC) concentration by dry weight.  A key distinction concerning 
definitions is addressed later in section 12608 of Title 12, where it is noted that hemp 
does not include “marihuana” and that the Schedule 1 status of tetrahydrocannabinol 
(THC), found in the Controlled Substances Act, will not apply to the minimal amount of 
THC found in hemp as it was defined earlier.  After clarifying the definition of hemp, 
sections 11101, 11106, 11112 and 11120 of Title 11 all make varying amendments to 
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include hemp under crop insurance (Agricultural Hemp Solutions).  This extension 
protects farmers under the Federal Crop Insurance Act which assists farmers in 
production and crop termination or crop failure (Hudak). 
The 2018 Farm Bill amends the Agricultural Marketing Act of 1946 to allow 
states a chance to propose a plan for growing and producing hemp, which can then be 
sent to the United States Department of Agriculture (USDA) for approval.  In order for 
the USDA to approve a state’s proposed plan, the plan must state where the hemp will be 
grown, how the THC levels will be tested, and how plants with THC levels exceeding 
0.3% will be disposed of.  If approved, that state may then grow hemp.  If denied, that 
state must comply with federal laws and regulations (United States Senate Committee on 
Agriculture, Nutrition, and Forestry).   
Research involving hemp is addressed in sections 7415 and 7125 of Title 7.  
Section 7415 deals with the legitimacy of industrial hemp research and requires a study 
and report on the “economic viability” of the hemp industry (domestic production and 
sales of industrial hemp) in the United States.  Section 7125 has been changed to include 
hemp in alternative and supplemental crops on which research projects can be conducted.  
It is important to note that while the 2018 Farm Bill does make changes to the production 
of hemp and allow research, it specifically notes in section 10112 that those amendments 
do not authorize interference with current laws on interstate commerce regarding hemp. 
The 2018 Farm Bill provides a clear definition of hemp, allows growth and 
production of hemp if through a USDA approved plan, extends protection for researchers 
and farmers who choose to work with hemp, and legalizes hemp under specific 
conditions and with considerable restrictions and regulations (United States Senate 
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Committee on Agriculture, Nutrition, and Forestry).  This bill does not have anything to 
do with state-legal cannabis programs, which are still illegal under federal law (Hudak).  
In regards to cannabidiol (CBD), this bill removes hemp-derived products from Schedule 
I status, which effectively legalizes CBD.  However, nowhere is it explicitly stated that 
CBD is legalized.  In fact, according to the 2018 Farm Bill, only very specific batches of 
CBD would be considered legal.  Only CBD produced following every part of this bill, 
following all federal and state regulations, and produced by a licensed grower would be 
considered legal.  Any other form of CBD products (even if produced under state-legal or 
medical cannabis programs) are considered illegal under federal law (Hudak).  This is a 
gray area where technicalities are difficult to enforce, and manually determining the 
origin of all CBD-containing products is unrealistic.  Another gray area is that although 
the 2018 Farm Bill essentially legalized CBD, most CBD products are still in violation of 
the Food Drug, and Cosmetic Act. 
Food, Drug, and Cosmetic Act 
 
 The Food, Drug, and Cosmetic Act (FDCA) is a set of laws giving the FDA 
authority to monitor the safety of foods, drugs, medical equipment, and cosmetics that 
was enacted by Congress in 1938 (Wikipedia).  The FDA website has stated that it has 
only approved one drug containing CBD, Epidiolex®, and specifically notes that it is 
currently illegal to market and sell CBD in addition to food or by labeling it as a dietary 
supplement (FDA).  The website also notes that CBD products are being marketed 
without proven health benefits, with potentially untrue claims, and under unknown 
quality, but makes a specific point to mention food.  The FDA strongly encourages 
pregnant women to avoid any form of marijuana while pregnant (including THC and 
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CBD isolates).  The U.S. Surgeon General advised to avoid THC since the substance may 
cross into the placenta and affect fetal brain development as well as linger in breastmilk.  
There is no conclusive evidence on CBD, so it is recommended for mothers to avoid it as 
well.   
 Interstate commerce of CBD or THC directly violates the Food, Drug, and 
Cosmetic Act.  Under the Q&A section of their website, the FDA states that food with an 
active drug ingredient of an approved drug or ingredients which are currently under 
clinical investigation are prohibited from interstate commerce.  This is interesting when 
taken into account with internet sales of CBD.  For the most part the FDA has been 
turning a blind eye and companies like Oki are being crafty with marketing, labeling their 
CBD-infused waters as having “active hemp ingredients” (Reiley).  However, the FDA 
sent out twenty-two warning letters to companies in 2019. 
Warning Letters from the FDA 
 The FDA website has a list of companies to which it has issued warning letters 
concerning unapproved new drugs and supplements which contain cannabidiol.  Most 
recently updated in November of 2019, the FDA sent letters to a total of twenty-two 
companies located in California, Texas, Oklahoma, Colorado, New York, Oregon, 
Florida, North Carolina, Arizona, Kentucky, Arkansas, Maine, New Jersey, and 
Washington for that calendar year (FDA).  Companies marketing products with 
unapproved claims or untested amounts of CBD were sent a letter addressing the 
marketing and selling of cannabidiol products.  As an example, the letter to Koi CBD 
LLC in California was sent a letter on the 22nd of November 2019 and followed the 
following format.  
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 The warning letter began by addressing the products of interest by name and the 
claims of each product.  The next issue to be covered was the misbranding of CBD 
containing products under varying sections of the Food, Drug, and Cosmetic Act 
(FDCA).  Koi CBD LLC was also selling CBD products targeted to treat animals, which 
was in violation of the FDCA.  The letter goes on to mention violation of interstate 
commerce law under the FDCA and the labeling and definition restrictions for dietary 
supplements, which CBD does not currently fall under.  The next header is titled 
“Unapproved New Drugs” and notes specific instances on Koi CBD LLC’s website 
which claim to know and promote benefits of CBD.  Lastly, the warning letter addresses 
adulterated human and animal foods.  Each letter follows this same general outline. 
 Although these warning letters were sent out, the FDA still struggles to enforce 
certain rules on companies that choose to market CBD products.  Dr. Amy Abernethy, 
principal deputy commissioner of the FDA and co-chair of CBD Policy Working group 
founded by the FDA, noted two important points in her testimony to Senate Agriculture 
Committee on July 25 of 2019.  First, she acknowledged that full regulation of CBD 
products as ingredients in food or supplements would require new laws from Congress, 
which could likely take up to five years to form and pass (Page).  Second, she implied 
that the FDA was hesitant to legitimize current over the counter CBD products.  This 
would decrease the need for prescription drugs like Epidiolex®, which would deter 
pharmaceutical companies from investing in the research to determine the full extent of 
what CBD could treat or help cure.  There is not enough current research available for the 
FDA to determine the safety and efficacy of CBD for certain populations and ailments, so 
pharmaceutical companies’ interest in the product is necessary to drive clinical trials 
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(Page).  Dr. Abernethy did concede that for the most part the FDA is turning a blind eye 
to the current CBD industry and is mainly focused on enforcing laws related to the 
marketing of cannabidiol.  Products containing CBD which are marketed with 
“unsubstantiated therapeutic claims” are the main concern of the FDA at this time (Page).   
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STATE REGULATION OF CANNABIDIOL 
 Just like with medical and recreational marijuana, states vary in their allowance of 
consumer use of CBD. 
Figure 2: US State Legalization Map 
 
 
 
From: https://commons.wikimedia.org/w/index.php?curid=2370050  
 
This is a current map as of 28 March 2020, from Wikipedia.  The blue states have 
fully legalized marijuana including CBD, while the green states will allow marijuana to 
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be used for medical purposes.  Differentiating between the green states, the light green 
states have legalized medical marijuana use as long as there is a low level of THC 
(indicating high levels of CBD), while the dark green states are unconcerned with the 
amount of THC.  Finally, the gray states have not legalized marijuana or cannabidiol in 
any form, adult use or medical use.  The states marked with a red letter D have 
decriminalized marijuana including cannabidiol (Wikipedia). 
Special State Laws of Interest 
 While most states have legalized hemp-derived CBD for seizures and epilepsy 
after the Farm Bill was revised in 2018, each state has its own particular rules and 
regulations regarding cannabidiol.  The source (hemp or marijuana), as well as the 
percentages of THC and CBD, and indications of CBD are the main categories to vary 
depending on the state. 
 California has legalized CBD for medical and recreational use, but prohibits the 
addition of CBD as a food ingredient until approved by the FDA as a safe ingredient, 
additive or supplement (CBD Project Awareness).  This rule applies to food intended for 
human consumption as well as animal or pet consumption.  An interesting way current 
businesses are evading this rule is by offering CBD as a side item on menus.  A CBD 
shot can be ordered and added to food or drink by the customer.  This is occurring in 
other states as well such as New York.   
 Delaware has also legalized medical use of CBD from hemp and marijuana but 
requires all patients as well as their caregivers to have an ID card that allows them to 
possess a maximum of 6 ounces of CBD.  The medical CBD from marijuana cannot have 
any more than 7% THC.  South Carolina however, requires CBD products to have 98% 
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CBD and only 0.9% of THC (CBD Project Awareness).  This is an area in which states 
vary greatly on what is allowed.  Hemp by definition in the 2018 Farm Bill is a strain of 
cannabis which has less than 0.3% THC; however, especially with states that have 
legalized CBD from marijuana this value varies. 
Minnesota and New Mexico have added specific qualifying medical conditions to 
their lists of approved reasons for prescribing CBD.  A few of the usual conditions 
include epilepsy, end-stage cancer, multiple sclerosis and Parkinson’s disease.  
Minnesota approved CBD for Alzheimer’s and obstructive sleep apnea while New 
Mexico was the first state to approve CBD for post-traumatic stress disorder (PTSD) 
patients (CBD Project Awareness). 
Idaho is one of three states that currently has restrictions on all forms of cannabis 
and CBD, even after the 2018 Farm Bill which legalized hemp on a federal level.  
Epidiolex®, the only FDA approved drug containing CBD, is the only exception to this 
rule.  This creates a significant gray area for Idaho citizens who may be able to use CBD 
legally under federal law but not under state law (CBD Project Awareness). 
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MISSISSIPPI REGULATION OF CBD 
Harper Grace’s Law 
Just as Charlotte Figi was the catalyst for change at the national level, Harper Grace 
Durval was the catalyst for change at the state level in Mississippi.  Harper Grace Durval 
began having seizures around 6 months of age and was diagnosed with Dravet 
Syndrome—the same diagnosis that Charlotte received (Gates).  Harper Grace’s mother, 
Ashley Durval, advocated for the legalization of CBD treatments in Mississippi for 
epileptic seizure patients like her daughter.  She stated that the current medications 
simply do not work and that they are quickly running out of options for anti-seizure 
medicines (WMC-TV). 
Harper Grace’s condition and Ashley Durval’s persistence in advocating for CBD use 
for severe epileptic patients in Mississippi ultimately lead to the passing of Harper 
Grace’s Law, signed into law in April of 2014 by Governor Phil Bryant (Wikipedia).  It 
originated as House Bill 1231 and passed with a majority vote in both the House and 
Senate.  Harper Grace’s Law allows cannabidiol in very limited context to be obtained 
from a physician who is licensed to practice in Mississippi.  The CBD allowed can be in 
either oil or resin form from a cannabis plant with at least 15% cannabidiol for oils or 50 
mg of cannabidiol per milliliter for diluted resins and a maximum of 0.5% 
tetrahydrocannabinol or THC content (Mississippi Legislature, Wikipedia).  Additionally, 
the CBD must be obtained or tested specifically through the National Center for Natural 
Products Research located at the University of Mississippi and be dispensed by the 
pharmacy at the University of Mississippi Medical Center in Jackson, Mississippi.  The 
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law is reserved for patients with “debilitating epileptic condition(s)” (FindLaw).  Harper 
Grace’s Law is one of the stricter laws regarding medicinal cannabis use among the states 
that have approved CBD for medical purposes (Wikipedia). 
UMMC Clinical Trial 
 As of 2017, even after the passing of Harper Grace’s Law, Mississippi still did not 
have the final approval needed from the federal government to begin clinical trials at the 
University of Mississippi Medical Center (UMMC) in Jackson, Mississippi (Gates).  Dr. 
Brad Ingram, the director of the Pediatric Comprehensive Epilepsy Center at UMMC, 
would be the one to oversee a small trial (roughly 5-10 patients) of CBD oil in severe 
seizures of young children if the 32-page proposal submitted to the FDA were approved 
(Gates).  He noted that while a lot of work had gone into creating the proposal, federal 
approval is ultimately out of anyone’s hands.  The approval process includes three federal 
agencies: The National Institutes of Health (NIH), the Food and Drug Administration 
(FDA), and the Drug Enforcement Agency (DEA).   
 Then in November of 2018 and UMMC had received the necessary approval from 
the DEA and FDA to begin trials.  Dr. Ingram stated that the study would be six months 
long with a maximum of ten patients and aimed to treat the “sickest of the sick” with 
“compassionate care” (Oeth).  A secondary consideration with a short, small trial was 
that of product availability after the study.  No one wants to be given a drug that works 
and then told that they will no longer have access to CBD.  Once the cannabidiol is 
produced and checked for quality, it is diluted and dosed using pharmaceutical grade 
sesame seed oil (Oeth).  The study produced excellent results, with most patients 
experiencing a drop in the number of seizures per month and all experiencing an 
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increased quality of life.  The current drug and dosages were not seen to cause any 
damage to developing brains or tolerability issues in the patients.  This clinical trial has 
been granted a one-year extension in the summer of 2019 and will be reassessed in the 
summer of 2020.   The FDA extension will allow more development of treatments for 
epileptic seizure patients who have not had success with traditional seizure drugs (Oeth). 
 Technically, this trial provides the only current legal access to cannabidiol in 
Mississippi.  So why are there so many products and stores openly selling and promoting 
CBD products, even in local pharmacies?  This is the gray area of law where enforcement 
(or lack thereof), specific marketing, purity, and definitions all come into play. 
Medical Marijuana on Mississippi November Ballot 
 Following all of the attention medical marijuana and CBD have gathered over the 
past few years, Mississippi will have Medical Marijuana on the ballot in November of 
2020.  The group Mississippians for Compassionate Care began an initiative that 
gathered 106,000 signatures, more than the 86,000 signatures required, to form Ballot 
Initiative 65 which is sponsored by Ashley Durval (Ramseth).  The goal is to legalize 
medical marijuana use in Mississippi allowing doctors to prescribe for specified 
conditions including cancer, epilepsy, multiple sclerosis, and Parkinson’s.  If approved, 
the Department of Health would regulate medical marijuana treatment centers and 
dispensaries.  While 77% of Mississippians seem to be in favor of legalizing marijuana 
for medical purposes, a few concerns have been raised about the medical legalization 
eventually leading to recreational legalization (Ramseth).  The other opposing arguments 
are that little is known about marijuana and how it interacts with certain medical 
conditions. 
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CONCLUSION 
 Cannabidiol holds promise for many different conditions but requires more 
clinical testing and research before any conclusions can be drawn. The data explored in 
this paper in part, support the hypothesis that CBD holds clinical promise for the 
treatment of conditions, and studies are being conducted in a rigorous way that meets 
FDA approval in the example of Epidiolex® or may do so in the future such as the CBD 
product in clinical trials here at the Universiy of Mississippi. But we also reviewed 
accounts of situations whereby CBD is not always being used for clinical conditions that 
have support or rigorous studies, or is CBD being used in compliance with local laws, 
such as in the state of Mississippi.  
The implications of future approvals of CBD are closer than we think. As this 
drug becomes more regulated and available from pharmacies, it will be necessary for 
physicians and pharmacists to have a current working knowledge of the topic and laws 
surrounding CBD as well as the available forms and dosing issues in order to ensure the 
best possible patient care. 
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